Regulonix
Tucson, AZ · Biotech · Private
Small molecule NRP-1 antagonists for pain management discovered through virtual screening
- Grants
- $2.4M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 2
- 0 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2016201720182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Regulators of NaV1.7 Channels: Novel Anti-Allodynic Drug Candidates | $299,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Regulators of NaV Channels Novel Anti Allodynic Drug Candidates | $299,999 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Discovery of T-type Calcium Channel Antagonists from Multicomponent Reactions and Their Application in Paclitaxel-induced Peripheral Neuropathy | $341,527 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Optimization of Betulinic Acid analogs for T-type calcium channel inhibition for non-addictive relief of chronic pain | $224,696 | |
| Federal grant | Department of Health and Human Services · Phase I · Inhibition of CaVα-β interaction with orally available small organic molecules for chronic pain | $400,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting the neuropilin-1 receptor (NRP-1)/VEGF-A axis for neuropathic pain | $419,470 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting the neuropilin-1 receptor (NRP-1)/VEGF-A axis for neuropathic pain | $419,470 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1999 | CLAIRIgene | — | — |
| 2000 | Compass Therapeutics | — | $256M |
| 2001 | NiKang Therapeutics | — | $200M |
| 2002 | Regulonix | — | — |
| 2003 | FORMATION VENTURE ENGINEERING FOUNDRY INC | — | — |
| 2004 | Converge Bio Inc. | — | $25M |
| 2005 | ALPHA YOUNG LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Inhibitors of the Surface Expression of the Voltage-Gated Sodium Ion Channel 1.7 (NaV1.7) and Their Therapeutic Usesapplication
- Inhibitors of the Surface Expression of the Voltage-Gated Sodium Ion Channel 1.7 (NaV1.7) and Their Therapeutic Usesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.